The use of adenoviral vectors for therapeutic delivery of genes via pulmonary application poses several problems in terms of immune responses. The purpose of this study was to determine whether polyethylenimine ( PEI ), a polycationic DNA carrier, can be used to deliver the IL -12 gene into the lungs of mice having microscopic osteosarcoma ( OS ) lung metastases. Incubation of SAOS -LM6 cells in vitro with PEI containing the murine IL -12 ( mIL -12 ) gene ( PEI:IL -12 ) resulted in expression of both the p35 and p40 subunits of IL -12 mRNA and production of mIL -12 protein. Using our newly developed OS nude mouse model, we demonstrated that treatment of mice using intranasal PEI:IL -12 resulted in significant IL -12 mRNA expression in the lung but not the liver. Furthermore, plasma IL -12 was undetectable after up to 4 weeks of intranasal PEI:IL -12 therapy given twice weekly. No IL -12 expression was seen following intranasal PEI therapy alone. The number of lung metastases in animals that received intranasal PEI:IL -12 twice weekly for 4 weeks starting 6 weeks after tumor inoculation was significantly decreased ( median, 11; range, 0 -47 ) compared with those that received PEI alone ( median, 89; range, 2 to >200; P = .012 ). Also, the size of the nodules was significantly smaller in the PEI:IL -12 -treated animals, with 90% measuring 0.5 mm in diameter compared with 56% in the PEI -alone group. Animals that received PEI alone also had numerous large nodules ( 3 -6 mm ) throughout the lungs. Intranasal therapy is a noninvasive way to administer agents and has the advantage of targeting the pulmonary region, resulting in higher concentrations in the tumor area. Additionally, delivery of IL -12 to the lung via the airway using PEI may avoid systemic toxicity. Because OS metastasizes almost exclusively to the lung, this may be a novel approach to the treatment of pulmonary OS metastases. Cancer Gene Therapy ( 2002 ) 9, 260 -266 DOI: 10.1038 / sj / cgt / 7700432
D espite multiple changes in the adjuvant chemotherapy regimens used to treat osteosarcoma (OS ), the 2-year metastasis -free survival rate in patients having this disease has stagnated at 65 -70%. 1 -3 The majority of OS patients who have a relapse do so within the first year while receiving chemotherapy. In these patients, the lung is the most common site of metastatic spread. Those who initially present with metastatic lung disease have an even higher rate of treatment failure, as no more than 15% achieve long -term metastasis -free survival. Although the majority of OS patients having pulmonary metastases can be rendered disease-free using thoracic surgery, 80 -85% will have a relapse in the lung within 1 year; 4, 5 salvage chemotherapy has been disappointing in improving this progression-free interval. This indicates that patients may benefit from new approaches and agents targeted specifically to pulmonary metastases.
Our laboratory has recently developed an experimental OS lung metastasis model in T cell -deficient nude mice to evaluate potential new therapeutic approaches. 6 In this model, microscopic pulmonary metastases are evident by 6 weeks following intravenous (i.v. ) injection of human LM6 OS cells, with visible tumor nodules present by 8 -10 weeks. Because the lung is the most common and often only site of OS relapse, we reasoned that local delivery of agents via aerosol or intranasal instillation may offer a unique therapeutic opportunity. Intranasal or aerosol therapy delivers the agent directly to the lung, increasing the concentration in the tumor area and potentially decreasing systemic toxic effects. Using our experimental OS lung metastasis model, we demonstrated that intranasal gene therapy using Ad.mIL -12 resulted in the inhibition of established pulmonary metastases. 7 Although the use of adenoviral vectors in gene transfer is presently being tested in clinical trials, the use of nonviral gene delivery techniques offers several advantages. Nonviral gene -delivery systems avoid the strong immune response that has limited gene expression and hampered the use of adenoviral gene therapy in many patients. 8 Additionally, liposomes (Lip) and polyethylenimine (PEI ) have both been shown to be efficient vectors for gene transfer in vivo. 9 -11 PEI is an organic macromolecule having the highest cationic charge density potential. 9 Lipid composition has been shown to play a major role in the transduction efficiency of Lip, with lysosomal degradation of DNA being a major problem. Use of PEI as a vector delivery system has avoided this problem. Direct injection of PEI /DNA complexes into newborn mouse brains showed efficient transfection of the cells in vivo.
12 Because of its high cationic charge density potential, PEI has the added advantage of retaining its cationic state at the physiological pH level. Also, the substantial buffering capacity of PEI may permit endosome buffering and, thus, prevent lysosomal and DNase degradation of DNA. 13 Our data indicate that PEI is an effective delivery vehicle for intranasal IL-12 gene therapy. Mice receiving PEI:IL -12 had significant IL -12 expression in lung tissue but not other organ systems. In contrast, Lip was not effective in transducing lung tissue.
Materials and methods

Reagents
Eagle's MEM, HBSS without Ca 2 + or Mg 2 + , nonessential amino acids, sodium pyruvate, MEM vitamins, L -glutamine, and 2.5% trypsin were purchased from Whittaker Bioproducts (Walkersville, MD ). Fetal bovine serum was purchased from Atlanta Biologicals (Norcross, GA ). All reagents were free of endotoxin as determined using the Limulus amebocyte lysate assay (sensitivity limit, 0.025 ng/ mL ) purchased from Sigma (St. Louis, MO ). PEI (25 kDa branched ) was purchased from Aldrich Chemical (Milwaukee, WI). A stock solution of PEI, pH 7.0-7.5, was prepared at a concentration of 4.3 mg /mL (0.1 M in nitrogen ) in phosphate -buffered saline. Lip, which were prepared at a concentration of 3 mg /mL, were a gift from Dr Berma Kinsey (Veterans Affairs Hospital, Houston, TX ) and were made up of bis -guanidinium -tren -cholesterol combined with dioleoylphosphatidyl ethanolamine.
14 Lip + pCA -IL -12 were prepared at a lipid:DNA ratio of 6:1 by diluting the DNA in water and slowly adding it to the lipid dispersion while vortexing as described previously. 14 
Vectors
The pcAGG plasmid containing mIL -12 ( pCA -IL-12 ) was a gift from Dr Jun -ichi Miyazaki (Osaka University Medical School, Yamadaka, Japan ). The plasmid was purified commercially by Bayou Biolabs (Harahan, LA ), was endotoxin free, and was quantitated using UV absorbance. Agarose gel analysis revealed the plasmids to be primarily in the supercoiled form with a small amount of nicked plasmid.
In addition, the bicistronic adenoviral vector carrying both the p35 and p40 cDNAs for the mIL -12 heterodimer, Ad.mIL-12, was used and propagated as described previously. 7, 15 An adenoviral vector containing the -galactosidase gene, Ad.gal, was used as a control for Ad.mIL -12. 7 
Cell lines
SAOS -LM6, a human OS cell line was developed by repetitive cycling through the lungs of nude mice. 6 These cells were maintained in Eagle's MEM supplemented with 1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM L -glutamine, two fold vitamins, and 10% heatinactivated (568C for 30 minutes ) fetal bovine serum. The monolayer culture of cells was maintained in 75-cm 2 tissue culture flasks (Costar, Cambridge, MA ) at 378C in a humidified 5% CO 2 incubator, tested periodically for mycoplasma contamination, and verified to be free of pathogenic murine viruses (M.A. Bioproducts, Walkersville, MD ).
Mouse model
Male, 4 -to 6-week -old, specific pathogen-free, athymic nude mice were purchased from Charles River Breeding Laboratories ( Kingston, MA ). The mice were maintained in an animal facility approved by the American Association of Laboratory Animal Care in accordance with current regulations and standards of the United States Department of Agriculture, the Department of Health and Human Services, and the National Institutes of Health. Mice were housed five to a cage and kept in a laminar flow cabinet under specific pathogen -free conditions for 2 weeks before use. Injection of 10 6 SAOS -LM6 cells into the mice i.v. resulted in microscopic metastases by 6 weeks, with visible lung nodules by 8-10 weeks. 6 
Cell transfection
PEI containing the pCA -IL -12 plasmid (PEI:IL -12 at a PEI nitrogen:DNA phosphate ratio of 10:1 ) was prepared by first diluting 3.03 l PEI stock solution into 10 mL medium and then adding it to 10 mL medium containing pCA -IL -12 at 2 g /mL, which was mixed by vortexing and incubated for 15 minutes at room temperature. Additionally, SAOS -LM6 cells in the exponential growth phase were seeded into 150-mm dishes overnight and then incubated with PEI or PEI:IL -12 for 24 hours at 378C. Expression mRNA of the p35 and p40 IL-12 subunits was confirmed using Northern blot analysis and RT-PCR.
Northern blot analysis
Total RNA was isolated from tissue or cells using Trizol reagent ( Life Technologies, Gaithersburg, MD ). Equivalent amounts of RNA (20 g /lane ) were size fractionated by electrophoresis in 1.0% agarose gels containing 6.6% formaldehyde and transferred to nylon membranes (Micron Separation, Westborough, MA ). The membranes were UV cross -linked with 120,000 J/cm 2 using a Stratalinker UV cross -linker (model 1800; Stratagene, La Jolla, CA ) and prehybridized using Rapid -hyb buffer (Amersham, Buckinghamshire, UK ). Probes for p35, p40, and GAPDH were labeled with [ -32 P ]dCTP using the Rediprime DNA labeling system ( Amersham ).
The membranes were exposed to Kodak XAR -5 film ( Eastman Kodak, Rochester, NY ) at À 708C. Expression was quantified by the densitometry of autoradiograms using the ImageQuant software program (Molecular Dynamics, Sunnyvale, CA ), and values were normalized to differences in GAPDH scanning densities.
RT -PCR
RT-PCR was performed using PTC -200 DNA Engine Peltier Thormal Cycle (MJ Research, Inclin Village, NV ). Five microgram of total RNA extracted from SAOS -LM6 cells transfected with PEI:IL -12 in vitro was reverse transcribed (RT ) using 1 l of oligo( dT ) primer (0.5 g/ l), 2l of 0.1 M DTT, 1 l ( 200 U ) of SuperScriptm II Rnas H -reverse transcriptase, 4 l of 5Â first -strand buffer, and 1 l of 10 mM dNTP mix ( Gibco -BRL, Grand Island, NY ) in a 20 -l reaction volume at 428C for 50 minutes, and then 708C for 15 minutes. RT-reaction products -cDNA were kept on ice, 5 l of cDNA samples (RT-reaction products) were amplified by PCR for 30 cycles, each cycle including 948C for 1 minute, 608C for 1 minute, and 728C for 1 minute with 5l of 10Â PCR buffer, 0.5 l/2.5 U of Taq DNA polymerase ( Roche Diagnostics, Indianapolis, IN ), 1 l of 10 mM dNTP mix, and 5 l of 10 mM of each murine IL -12 primer: sense (forward primer ) 5 0 -ATGTGTCAATCAC-GCTACCTC, antisense ( reverse primer ) 5 0 -TCAGG-CGGAGCTCAGATAG for murine IL-12 p35, and sense 5 0 -ATGTGTCCTCAGAAGCTAAC, antisense 5 0 -TCCTA-GGATCGGACCCTG for murine IL -12 p40. 15 As internal control for quantitative, 4 l of 5 M 18 s primer / competimer ( 18 s internal standard, 324 bp, Ambion, Austin, TX ) was used to amplify. Total volume was 50 l. The primer was designed to produce a 648-bp fragment for mIL -12 p35 and 1010 bp for mIL -12 p40. The PCR products were isolated by electrophoresis on 2% agarose gel stained with ethidium bromide, and visualized under UV light. The results were quantitated by using Quantity one machine ( Bio -Rad, Hercules, CA ).
In vitro mIL -12 protein production SAOS-LM6 cells (10 4 cells/0.5 mL ) were seeded into 24 -well plates overnight. The cultures were then treated with PEI:IL -12 (1 or 2 g /mL of IL -12 ) or PEI alone for 24 hours. At the end of treatment, the cultures were washed twice with HBSS and then refed with fresh medium. The supernatants were collected at 24, 48, 72, and 96 hours and 1 week after incubation, centrifuged at 12,000 rpm to sediment residual cells and debris, aliquoted, and stored at À 808C.
Intranasal therapy
Mice were anesthetized with metophane before inhalation therapy. A total of 25 l of dH 2 O -containing Lip or Lip:IL -12 ( 6:1 wt/ wt ) or undiluted virus ( 3.3Â10 11 pfu /mL Ad.mIL-12 or 1Â10 10 pfu/mL Ad.gal [ the maximal concentration of each virus available ]) was introduced in a dropwise manner to both nostrils twice weekly for 2 weeks. To determine whether the mIL -12 gene could be transduced into lung tissue using PEI, mice were anesthetized with isoflurane ( Burns Vet Supply, Carrollton, TX ) using the Multistation Rodent Anesthetic Delivery and Scavenging System ( MDS Matrix, Orchard Park, NY ); 25 l PEI or PEI:IL -12 (3.03 l PEI:20 g IL-12) was instilled intranasally twice weekly for 2 weeks. The mice were sacrificed 24 hours after completing treatment, and the lungs and livers were removed and homogenized. Total RNA was extracted using Trizol reagent, and RNA expression was determined using Northern blot analysis.
To determine whether mIL -12 protein was produced in the lung tissue and induced systemically, mice received intranasal PEI or PEI:IL -12 twice weekly for 2 weeks. Blood 
Cancer Gene Therapy
Intranasal PEI:IL -12 gene therapy for metastatic OS S -F Jia et al was collected from their kidney artery under anesthesia at 24 hours after completing treatment, and the isolated serum was aliquoted and stored at À 808C. The lungs were removed, washed twice with PBS (48C ), and homogenized with lysis buffer [ 20 mM Tris pH 8, 137 mM NaCl, 10% ( wt/ vol ) glycerol, 1% ( wt/ vol ) Triton, and 2 mM EDTA with 0.1 mM PMSF, 1 g/ mL of aprotinin, 1 g/mL of leupeptin, and 1 g /mL of pepstatin ]. The lysis products were vortexed, incubated on ice for 20 minutes, and then spun. The supernatants were collected and stored at À 808C. The blood obtained from tumor-bearing mice that had received PEI:IL -12 for 4 weeks was also collected, and serum was isolated and stored at À 808C. The lysis production from lungs and the serum mIL -12 protein level was measured using the solid-phase sandwich ELISA ( Endogen, Woburn, MA ) according to the manufacturer's recommendations.
In vivo IL -12 treatment
SAOS-LM6 cells ( 10 6 ) were injected via the lateral tail vein. Six weeks later, twice weekly intranasal therapy using 25 l of PEI or PEI:mIL -12 (20 g mIL -12 /mouse) was initiated and given for 4 weeks. Four weeks after the completion of therapy (week 14), the animals were sacrificed. The lungs were removed and fixed in Bouin's solution to examine the effect of this intranasal therapy on OS pulmonary metastases. The size of nodules of the metastatic tumor on the surface of the lung was measured by using calipers. The number of metastatic tumor nodules on the lung surface was counted under a dissecting microscope as previously described. 6, 7 In addition, the blood was collected, and the isolated plasma was stored at À 808C. Figure 1 , A and B shows that PEI was able to deliver the IL -12 gene into SAOS -LM6 cells in vitro with subsequent expression mRNA of both the p35 and p40 subunits of IL -12 by Northern blot analysis ( Fig 1A ) and RT-PCR (Fig 1B ) . LM6-#6, a cloned cell line derived from SAOS -LM6 cells following transfection with the pcAGG plasmid containing mIL -12 and selection in G418, 7 was used as a positive control. PEI alone had no effect on the cellular expression of IL -12. Also, Figure 2 shows that mIL -12 protein was produced and secreted by the SAOS -LM6 cells following exposure to PEI:IL -12, with peak production on day 2. mIL -12 protein production was detected for up to 7 days. No mIL -12 protein was detected in cultured supernatants from cells incubated with medium alone or medium containing PEI (Fig 2) . Cultured supernatants from LM6-#6 contained 6 -fold more IL -12 ( >5000 pg/mL, data not shown).
Results
Vector efficiency of PEI in vitro
Vector efficiency of PEI in vivo
We next determined whether PEI could transfer the IL-12 gene to lung tissue following intranasal instillation. Mice The cultured supernatants were collected again at 48, 72, and 96 hours and on day 7. The IL -12 protein level was measured using ELISA.
Cancer Gene Therapy
Intranasal PEI:IL -12 gene therapy for metastatic OS S -F Jia et al were treated intranasally with PEI:IL -12 or Lip + pCA -IL -12 twice weekly for 2 weeks. Intranasal Ad.mIL -12 served as a positive control. 7 The mice were sacrificed 24 hours after the final treatment; their lungs and livers were removed and homogenized, and RNA was extracted. As shown in Figure 3 , the mice that received Ad.mIL -12 intranasally had significant IL -12 expression in the lungs. Also, both the p40 and p35 subunits were present. Similarly, mice that received PEI:IL -12 intranasally (lane 4) but not PEI alone ( lane 5 ) had significant IL -12 expression in the lung tissue, although it was somewhat lower than that stimulated by Ad.mIL -12 treatment. In contrast, Lip + pCA -IL-12 were not effective in transducing lung tissue (lane 6 ). The induction of IL -12 expression in the lung following intranasal instillation of PEI:IL -12 was not secondary to the intranasal procedure or a nonspecific effect of lung irritation because PEI alone, Lip, and Ad.gal all failed to induce IL -12 expression in the lung following intranasal instillation ( Fig 3; lanes 3, 5, and 7 ) . These data indicated that PEI effectively delivers the IL -12 gene intranasally and is superior to Lip. Additionally, the IL -12 protein was also detected in mouse lung tissue by ELISA. As shown in Table 1 , both the p70 and the p40 subunit levels were higher in the lung of mice that received intranasal PEI:IL -12 compared to those that received PEI alone or control mouse. The IL-12 p70 protein level in the mice that received intranasal PEI:IL -12 was 2.3-and 2.4 -fold higher compared to those received PEI. Following intranasal PEI:IL -12 we were unable to detect IL-12 mRNA expression in the liver using Northern blot analysis (data not shown ). This data combined with the data above indicate selective gene delivery to the lung. Furthermore, no mIL -12 protein was detected in the plasma following PEI:IL -12 instillation (data not shown).
Effect of intranasal PEI:IL -12 on lung metastases
Having shown that mIL -12 can be expressed specifically in the lung after PEI:IL -12 treatment, the effect of intranasal PEI:IL -12 therapy on the formation of pulmonary OS metastases was assessed. Six weeks after SAOS -LM6 cell injection, mice were treated intranasally with PEI or PEI:IL -12 twice weekly for 4 weeks. Mice that received PEI:IL -12 had significantly fewer metastases (Fig 4 ) than did those that received PEI ( median, 11; range, 0 -47 vs median, 89; range, 2 to >200; P= .012 ). In addition, the sizes of the metastases were smaller in the PEI:IL -12-treated mice ( 90% measuring 0.5 mm in diameter compared with 56% in the PEI group ). Mice that received PEI alone developed numerous large pulmonary tumors throughout the lung ranging in size from 3 to 6 mm. At the end of the 4 week therapy, again we were able to detect IL -12 mRNA in the lung but not the liver ( data not shown ).
Discussion
The present study demonstrated that PEI can be used to deliver IL -12 to human OS cells in vitro and to the lung in vivo. Incubation of SAOS -LM6 cells with PEI:IL -12 in vitro resulted in expression of both the p35 and p40 subunits of IL -12 mRNA and production of mIL -12 protein.
Furthermore, intranasal instillation of PEI:IL -12 resulted in local IL -12 mRNA and protein expression in the lung. This method of gene delivery to lung tissue appeared to be selective as IL -12 mRNA was not detected in the liver. Similarly, plasma IL -12 was undetectable following as much as 4 weeks of intranasal PEI:IL -12 therapy.
IL -12 is a cytokine that has antiangiogenic as well as immunostimulatory activity.
16 -20 IL -12 activates NK 24 -26 We hypothesized that local IL -12 gene therapy targeted to the lung can result in a high concentration of IL-12 at the metastatic tumor site, thus avoiding the toxic effects associated with systemic delivery of the protein. Therefore, local gene therapy targeted to the lung is an appealing therapeutic approach for OS, as the lung is the most common and often only site of metastasis. Additionally, the concentration of the drug or cytokine and level of gene transfer at the metastatic site plays a critical role in inducing tumor regression.
Adenoviral and retroviral vectors are currently used in the clinical setting to deliver genes to cells and tissues for the purpose of correcting mutant or absent gene products. The majority of the studies of these vectors involve the use of intratumoral or i.v. vector injection. Viral vectors have limitations, however, due to their potential for promoting genomic rearrangement and stimulating an immune response. 27 The immune response induced by an adenovirus can lead to the rapid elimination of the vector, resulting in reduced effectiveness on subsequent administration. 8 Nonviral vectors offer several advantages over viral ones and have received increasing attention as potential vehicles for gene delivery in clinical practice. Specifically, PEI, a cationic polymer, has been shown to be an effective gene delivery vehicle in vivo, 28 -32 and PEI /DNA complexes have been shown to be stable and to deposit uniformly throughout the lung when administered in aerosol form. 30, 31 Our data demonstrated that intranasal PEI:IL -12 given twice weekly for 4 weeks resulted in the regression of pulmonary OS metastases. Although using PEI to deliver the IL-12 gene to the lung resulted in slightly lower IL-12 expression when compared with delivery using an adenoviral vector, the expression level (including RNA and protein ) was sufficient to result in the eradication of established microscopic disease. Also, the antitumor activity of PEI:IL -12 was unlikely to be secondary to a nonspecific plasmid effect, as aerosol PEI:CAT resulted in a lack of inhibition of tumor growth ( data not shown ).
The mechanism by which IL -12 exerts its antitumor activity is not fully understood. T cells play a critical role in mediating the antitumor activity of IL-12 in many of the animal tumor models described previously. 22, 23 However, the studies described here used nude mice. Activated T cells are therefore unlikely to play a major role in mediating tumor regression in this animal model. In contrast, NK cells, which are also activated by IL -12, are functional in nude mice and may contribute to the therapeutic efficacy of PEI:IL -12. Studies are now ongoing in our laboratory to determine the role of NK cells in the antitumor activity seen in this model.
A major challenge in gene therapy is the construction of vector systems that deliver genes to cells with a high degree of efficacy but induce minimal tissue toxicity and antivector immunity. PEI is an excellent nonviral vector candidate for delivering the IL -12 gene to the lung via intranasal instillation. Specifically, our data showed induction of IL -12 in the tumor organ environment with subsequent tumor regression. Therefore, we conclude that the intranasal route may be a viable way to deliver IL -12 gene therapy to the lung. Additionally, local therapy using PEI:IL -12 may offer a unique approach to treating OS metastases in the lung.
